#fda-approval

1 article tagged #fda-approval.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

Editorial lifestyle photograph illustrating a guide to Foundayo orforglipron oral GLP-1
GuideGuidesApril 29, 202614 min read

Foundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required

Updated April 29, 2026: Foundayo (orforglipron) is the first non-peptide GLP-1 pill for weight loss, FDA-approved April 1, 2026. Produces 12.4% body weight loss over 72 weeks per ATTAIN-1 trial. ACHIEVE-4 (April 2026): 57% lower all-cause death vs insulin glargine (HR 0.43, 2,700 patients). Self-pay starts at $149/month (starting dose) via LillyDirect, $299/month at maintenance doses. No food or water restrictions, take any time.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

TrimRx

7.8/10
$149/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

SkinnyRx

7.3/10
$199/mo·Compounded

Embody

7.3/10
$149/mo·Compounded

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.